GlassScriptPhysician profile
Muhammad Tahir
NPI 1275611790
$1,155.82
in general payments reported to CMS, 2019-2025
23 companies · $62.03 in 2025
The $62.03 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2020: $104 · 2021: $100 · 2022: $284 · 2023: $157 · 2024: $329 · 2025: $62.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $548.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $548.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $253.27 | 2021-2022 | |
| Abbvie INC. | $171.29 | 2021-2024 | Dalvance, Avycaz |
| Amarin Pharma, INC. | $105.20 | 2019-2021 | |
| Insmed, INC. | $67.88 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $64.75 | 2024 | Ninlaro |
| Scpharmaceuticals INC. | $59.42 | 2024 | |
| Alexion Pharmaceuticals, INC. | $50.85 | 2024 | Ultomiris |
| Janssen Pharmaceuticals, INC | $42.91 | 2022-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $41.09 | 2019-2021 | |
| Eisai INC. | $30.05 | 2024 | |
| Lilly USA, LLC | $28.92 | 2024 | Mounjaro |
| Stemline Therapeutics INC. | $27.82 | 2024 | Orserdu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.65 | 2025 | Jascayd |
| Emd Serono, INC. | $27.16 | 2023 | Tepmetko |
| Jazz Pharmaceuticals INC. | $25.35 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $22.48 | 2022 | |
| Philips North America LLC | $21.56 | 2023 | |
| Shield Therapeutics INC | $20.35 | 2025 | |
| Pfizer INC. | $20.06 | 2019 | |
| Mannkind Corporation | $18.23 | 2019 | |
| Allergan, INC. | $15.50 | 2020 | |
| Amgen INC. | $14.03 | 2025 | Repatha, Otezla |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Tahir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.